Wall Street brokerages predict that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will post earnings per share (EPS) of ($0.33) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.29). Corvus Pharmaceuticals reported earnings per share of ($0.36) in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is expected to issue its next quarterly earnings results on Thursday, March 5th.
On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.60) to ($1.47). For the next financial year, analysts anticipate that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.39) to ($1.06). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05.
Shares of CRVS stock opened at $3.45 on Wednesday. The stock has a 50 day moving average of $3.25 and a 200 day moving average of $3.93. The company has a current ratio of 9.23, a quick ratio of 9.23 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals has a twelve month low of $2.53 and a twelve month high of $8.10.
Institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $50,000. Paloma Partners Management Co purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $149,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $223,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Corvus Pharmaceuticals by 9.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 64,325 shares of the company’s stock valued at $241,000 after buying an additional 5,374 shares in the last quarter. Finally, Fosun International Ltd increased its position in shares of Corvus Pharmaceuticals by 7.7% in the second quarter. Fosun International Ltd now owns 184,116 shares of the company’s stock valued at $624,000 after buying an additional 13,142 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Article: Stocks Increasing Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.